Stock ASND ASCENDIS PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ascendis Pharma A/S

Equities

ASND

US04351P1012

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
142.1 USD +1.38% Intraday chart for Ascendis Pharma A/S -2.16% +12.82%
Apr. 19 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
Apr. 18 European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT

Evolution of the average Target Price on Ascendis Pharma A/S

Price target over the last 5 years

History of analyst recommendation changes

77.oQkk3_L3ZU1Tg22pLppgnKCQRCWvsgp4J9H06k3hlf4.8UdLuYvHMhohxADIdskn7-inBknb800scqHCiCiIx6eUY2yAmYU2eQDlVQ~616059d0645af181e1b6738030ee56d9

Analyst Recommendations on Ascendis Pharma A/S

JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Price Target on Ascendis Pharma to $173 From $152, Keeps Overweight Rating MT
Wedbush Raises Price Target on Ascendis Pharma to $207 From $202, Maintains Outperform Rating MT
Wedbush Raises Ascendis Pharma's PT to $202 From $200, Keeps Outperform Rating; Says Among Top Picks for 2024 MT
Jefferies Starts Ascendis Pharma With Buy Rating, $150 Price Target MT
Wells Fargo Adjusts Ascendis Pharma Price Target to $149 From $137, Maintains Overweight Rating MT
Wedbush Adjusts Ascendis Pharma A/S Price Target to $200 From $192, Maintains Outperform Rating MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $116 From $113, Maintains Equalweight Rating MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $113 From $109, Maintains Equalweight Rating MT
Wedbush Raises Ascendis Pharma's Price Target to $192 From $187 After Model Adjustments, Keeps Outperform Rating MT
Wedbush Lifts Ascendis Pharma's Price Target to $187 From $186, Keeps Outperform Rating MT
Wedbush Lowers Ascendis Pharma's Price Target to $186 From $195 After Model Adjustments, Keeps Outperform Rating MT
Morgan Stanley Adjusts Ascendis Pharma's Price Target to $109 From $107, Keeps Equalweight Rating MT
Credit Suisse Raises Ascendis Pharma's Price Target to $89 From $82 After Q1 Skytrofa Revenue Beat Consensus, Keeps Neutral Rating MT
Oppenheimer Downgrades Ascendis Pharma to Perform From Outperform, Removes $148 Price Target MT
Citigroup Adjusts Ascendis Pharma Price Target to $146 From $163, Maintains Buy Rating MT
Morgan Stanley Downgrades Ascendis Pharma to Equalweight From Overweight, Adjusts Price Target to $108 From $151 MT
BofA Securities Adjusts Price Target on Ascendis Pharma to $92 From $132, Keeps Buy Rating MT
Wells Fargo Cuts Ascendis Pharma's Price Target to $139 From $177, Maintains Overweight Rating MT
Evercore ISI Lowers Ascendis Pharma's Price Target to $140 From $160, Maintains Outperform Rating MT
Goldman Sachs Lowers Ascendis Pharma's Price Target to $155 From $175, Maintains Buy Rating MT
Credit Suisse Downgrades Ascendis Pharma to Neutral From Outperform, Lowers Price Target to $82 From $130 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
133.5 EUR
Average target price
166.7 EUR
Spread / Average Target
+24.88%
High Price Target
244.4 EUR
Spread / Highest target
+83.05%
Low Price Target
106.1 EUR
Spread / Lowest Target
-20.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ascendis Pharma A/S

JPMorgan Chase
Wells Fargo Securities
Citigroup
Wedbush
Cantor Fitzgerald
Jefferies & Co.
Morgan Stanley
Credit Suisse
Oppenheimer
BofA Securities
Evercore ISI
Goldman Sachs
SVB Securities LLC
Berenberg Bank
SVB Financial
SVB Leerink
Cowen
Canaccord Genuity
Stifel Nicolaus

Ratings for Ascendis Pharma A/S

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ASND Stock
  4. Consensus Ascendis Pharma A/S